Amphastar Pharmaceuticals (AMPH) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $825.42M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Yongfeng Zhang |
| IPO Date | 2014-06-25 | CAGR | 13.76% |
| Employees | 1,976 | Website | www.amphastar.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.61% | Total Yield | 2.61% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $1.39B | P/E | 6.39 | Forward P/E | 6.24 | PEG | -0.16 |
| P/S | 2.03 | P/B | 1.96 | P/CF | 9.05 | P/FCF | 11.01 |
| Sales | $720.53M | Sales 1Y | -1.06% | Sales 3Y | 38.93% | Sales 5Y | 95.7% |
| EPS | $2.93 | EPS 1Y | -39.86% | EPS 3Y | -7.26% | EPS 5Y | 3516.56% |
| Sales QoQ | -6.52% | EPS QoQ | -72.55% | Sales QoQ Avg | 0.3% | EPS QoQ Avg | -12.85% |
| Gross Margin | 47.34% | Operating Margin | 16.2% | Profit Margin | 11% | ROCE | 7.87% |
| ROA | 5% | ROE | 10% | Altman Z Score | 2.15 | Piotroski Score | 6 |
| Current Ratio | 3.85 | Quick Ratio | 2.82 | Cash Ratio | 1.04 | Op. CF Ratio | 0.29 |
| Debt/Equity | 0.89 | Debt/Assets | 0.42 | Lt Debt/Equity | 0.87 | Lt Debt/Cap. | 0.44 |
| Intrst Cov. | 4.53 | Inventory Turnover | 2.23 | Asset Turnover | 0.44 | Receivables Turnover | 4.87 |
| Enterprise Value | $1.39B | P/E Ratio | 6.39 |
| Forward P/E | 6.24 | PEG Ratio | -0.16 |
| P/S Ratio | 2.03 | P/B Ratio | 1.96 |
| P/CF Ratio | 9.05 | P/FCF Ratio | 11.01 |
| EPS | $2.93 | EPS Growth 1Y | -39.86% |
| EPS Growth 3Y | -7.26% | EPS Growth 5Y | 3516.56% |
| Revenue Growth 1Y | -1.06% | Gross Margin | 0.47% |
| Operating Margin | 0.16% | Profit Margin | 0.11% |
| ROE | 0.1% | ROA | 0.05% |
| ROCE | 0.08% | Current Ratio | 3.85 |
| Quick Ratio | 2.82 | Cash Ratio | 1.04 |
| Debt/Equity | 0.89 | Interest Coverage | 4.53 |
| Altman Z Score | 2.15 | Piotroski Score | 6 |
Amphastar Pharmaceuticals (AMPH) valuation & financials
Amphastar Pharmaceuticals (AMPH) has a market capitalization of $825.42M and trades at a price-to-earnings ratio of 6.4. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Amphastar Pharmaceuticals's revenue grew -1.1% over the last year.
Amphastar Pharmaceuticals's next earnings report is scheduled for August 6, 2026 after market close; analysts estimate EPS of $0.63.
Amphastar Pharmaceuticals (AMPH) — frequently asked questions
When does Amphastar Pharmaceuticals (AMPH) report earnings next?
Amphastar Pharmaceuticals is expected to report earnings on August 6, 2026 after market close. Analysts estimate EPS of $0.63.
What is Amphastar Pharmaceuticals's market cap?
Amphastar Pharmaceuticals (AMPH) has a market capitalization of $825.42M.
What is AMPH's P/E ratio?
Amphastar Pharmaceuticals trades at a price-to-earnings ratio of 6.4, with trailing twelve-month EPS of $2.93.
How fast is Amphastar Pharmaceuticals growing?
Amphastar Pharmaceuticals's revenue grew -1.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)